Orchestra Biomed Hldgs Inc (OBIO)

$5.28 -0.16 (-2.94%)
Market Cap 200.71M
Revenue (ttm) 2.76M
Net Income (ttm) -49.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,779.71%
Debt to Equity Ratio 0.00
Volume 58,500
Avg Vol 108,614
Day's Range N/A - N/A
Shares Out 38.01M
Stochastic %K 30%
Beta 0.53
Analysts Strong Sell
Price Target $15.67

Latest News on OBIO

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 7 weeks ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 4:12 PM EST - 2 months ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 5 months ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 8:43 AM EDT - 8 months ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:58 PM EDT - 8 months ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Apr 30, 2024, 8:30 AM EDT - 9 months ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 27, 2024, 4:17 PM EDT - 10 months ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 26, 2024, 8:00 AM EDT - 10 months ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 7, 2024, 8:00 AM EST - 11 months ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Mar 6, 2024, 8:37 AM EST - 11 months ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 1 year ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 4:21 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed to Present at Upcoming Investor Conferences

Nov 9, 2023, 4:42 PM EST - 1 year ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Sep 19, 2023, 7:30 AM EDT - 1 year ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:34 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Aug 8, 2023, 8:30 AM EDT - 1 year ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Jun 7, 2023, 8:30 AM EDT - 1 year ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 9:15 AM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Feb 24, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Jan 27, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Jul 5, 2022, 8:00 AM EDT - 2 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2